J. Dorca

发表

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

G. Ribas, P. Nuciforo, A. Prat, 2021, Frontiers in Oncology.

Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients

R. Porta, A. Blancafort, G. Oliveras, 2014, Menopause.

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

J. Brunet, S. Verdura, E. Cuyás, 2019, Front. Oncol..

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

J. Brunet, S. Verdura, E. Cuyás, 2019, Aging.

Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

B. Martín-Castillo, J. Bosch-Barrera, J. Menéndez, 2012, Oncotarget.

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

J. Brunet, S. Verdura, E. Cuyás, 2019, Journal of clinical medicine.

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

J. Carles, M. Margelí, J. Aparicio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Stratification of cancer and diabetes based on circulating levels of formate and glucose

Alexei Vazquez, B. Martín-Castillo, J. Menéndez, 2019, Cancer & metabolism.

Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.

J. Carles, B. Mellado, L. Paz-Ares, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas

E. Cuyás, E. López-Bonet, B. Martín-Castillo, 2015, Oncotarget.

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

A. Segura‐Carretero, E. Cuyás, E. López-Bonet, 2013, Oncotarget.

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2015, Oncotarget.

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.

J. Carles, L. Paz-Ares, J. Aparicio, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study

A. Segura‐Carretero, S. Verdura, E. Cuyás, 2018, Oncotarget.

403PPHASE II STUDY EVALUATING ORAL VINORELBINE AS A SINGLE-AGENT AS FIRST-LINE CHEMOTHERAPY FOR METASTATIC BREAST CANCER PATIENTS WITH BONE METASTASES (NORBREAST-228 TRIAL): FIRST EFFICACY RESULTS.

E. Espinosa, M. Benasso, M. Błasińska-Morawiec, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

E. López-Bonet, B. Martín-Castillo, J. Menéndez, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P1-10-01: Safety and efficacy of neoadjuvant metformin with trastuzumab and chemotherapy in women with HER2-positive early breast cancer: A randomized, open-label, multicenter, phase 2 trial

S. Verdura, E. Cuyás, E. López-Bonet, 2018 .